Open AccessTenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients
Author(s) -
Anton Pozniak,
Joel E. Gallant,
Edwin DeJesus,
José Ramón Arribas,
Brian Gazzard,
Rafael Campo,
Shan Shan Chen,
Damian J. McColl,
Jeffrey Enejosa,
John J. Toole,
Andrew Cheng
Publication year - 2006
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/01.qai.0000245886.51262.67
Subject(s) - efavirenz , emtricitabine , lamivudine , tenofovir , zidovudine , virology , medicine , antiretroviral drug , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , viral load , viral disease , virus , hepatitis b virus
In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented.